As many of you know, a primary 'mortality risk' with Asthma is 'fatal choking' resulting from Airway Sputum / Mucus. Not a particularly 'charming' way to Exit. (By the way, If you don't have time to read all of this - somewhat wordy - Post, please skip to my '2 Questions' near the end).
Airway Sputum is a particular interest of mine. Especially, how to prevent or minimise it.
Many Asthmatics who suffer from prominent Type 2 Asthma Inflammation, may well have symptoms that include 'breathing restrictions' due - or 'partly' due - to excessive Airway Sputum. (This 'might' also apply to other Asthma 'Types').
One theory concerning Sputum Production / Over Production (and how, perhaps, to reduce it) centres around Calcium Receptors. Note, this does 'not' necessarily imply that 'Dietary' Calcium is a contributor to Sputum / Mucus Production (and to Asthma Symptoms) although it's possible that some 'relationship' to dietary calcium (important for general health) may, in future, be identified. No rush just yet, however, to give up on 'Dairy' Produce.
There's a gap in my current knowledge concerning developments relating to Calcium Receptors / CASRs - i.e. what has happened since 2015 Research into 'Calcium Antagonists / Channel Blockers & Asthma' took place. This 'gap' includes a lack of knowledge of any subsequent research into the specific calcium antagonist / channel blocker 'Gallopamil', with respect to Asthma Treatment. (Particularly, that drug's 'potential' ability to reverse Airway Smooth Muscle Growth, which blights so many Asthma Suffers). Therefore, maybe someone can answer my Questions below.
QUESTIONS:
a) Has anyone been treated for Asthma with either Gallopamil, or any other drug that targets processes related to Calcium Receptors / CASRs?
b) Likewise, is anyone participating in a 'related' Drug Trial (and, if so, hows it working out for you)?
PS
If you're interest in some recent research that may have a bearing on this topic, I've provided a link (below) BUT the Article is not, primarily, aimed at the General Public, so is therefore somewhat 'technical'.
drugtargetreview.com/news/3...
Thanks in advance for any reply.